+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and effectiveness of the Mosaic Injectable Dermal Implant for treating age-related midface volume loss in adults aged 22 years and older. This study aims to track any medical issues participants may experience over 12 months after treatment and measure how much the implant improves midface volume six months after injection. Participants will receive up to 12 mL of the Mosaic Injectable Dermal Implant, divided into two injections spaced one month apart, with a maximum of 6 mL per session. If needed, a touch-up injection may be given one month after the initial treatment. The implant is delivered via injections to the midface to restore volume. During the study, participants will visit the clinic after each injection and at 3, 6, and 12 months post-treatment for facial photos to document volume changes. They will also keep a diary for 30 days after each injection to record any symptoms possibly related to the treatment. Researchers will monitor adverse events and evaluate the implants effectiveness using standardized volume scoring at set intervals throughout the year-long study.

Age: 22Years +All GendersPhase Not Applicable
5 locations